Table 1 Clinical characteristics of the study population
Parameter | CFRT/chemo 28 | SBRT/Chemo 27 | SBRT/NFV 45 | P1-valued | P2-valued |
|---|---|---|---|---|---|
Age (years) | 0.172a | ||||
Median (range) | 61 (49–76) | 66 (43–96) | 62 (34–79) | ||
Gender | 0.197 b | ||||
male | 12 (43%) | 15 (56%) | 29 (64%) | ||
female | 16 (57%) | 12 (44%) | 16 (36%) | ||
Tumor location | 0.080 b | ||||
Head/neck | 25 (89%) | 21 (78%) | 43 (96%) | ||
Body/tail | 3 (11%) | 6 (22%) | 2 (4%) | ||
Tumor Stage | 0.029b | 0.088b | |||
IIA | 16 (57%) | 9 (33%) | 14 (31%) | ||
IIB | 4 (14%) | 11 (41%) | 13 (29%) | ||
III | 8 (29%) | 5 (19%) | 18 (40%) | ||
IV | 0 (0%) | 2 (7%) | 0 | ||
Subsequent Resection | |||||
yes | 9 (32%) | 10 (37%) | 13 (29%) | 0.763 b | |
no | 19 (68%) | 17 (63%) | 32 (71%) | ||
Chemotherapy | |||||
5FU or Capecitabine | 28 (100%) | 27 (100%) | 0 | ||
Nelfinavir | 0 | 0 | 45 (100%) | ||
Dose/fractionation | |||||
1.8Gy*13 = 23.4Gy | 1 (3.6%) | ||||
1.8Gy*17 = 30.6Gy | 1 (3.6%) | ||||
1.8Gy*28 = 50.4Gy | 20 (71.4%) | ||||
2.0Gy*4 = 8Gy | 1 (3.6%) | ||||
2.0Gy*25 = 50Gy | 4 (14.2%) | ||||
2.5Gy*17 = 42.5Gy | 1 (3.6%) | ||||
5GY*5 | 6 (22%) | 8 (18%) | |||
6GY*5 | 4 (15%) | 3 (7%) | |||
7GY*5 | 17 (63%) | 9 (20%) | |||
8GY*5 | 0 | 25 (55%) | |||
Baseline TCLs (X 103/µl) | 0.740 a | ||||
Median (range) | 1.48 (0.5–2.8) | 1.43 (0.4–3.3) | 1.38 (0.3–2.6) | ||
Lowest TCLs (X 103/µl) | < 0.0001 c | 1.000c | |||
Median (range) | 0.29 (0–1.6) | 0.74 (0.1–1.5) | 0.68 (0–1.6) | ||
Days to Lowest TCLs | 0.281 c | ||||
Median (range) | 29 (13–38) | 25 (0–40) | 21 (0–40) | ||
Slope of TCLs Change (X 103/µl per day) | < 0.0001c | 0.242c | |||
Median (range) | −0.021 (−0.05–0.02) | −0.012 (−0.09–0.01) | −0.008 (−0.03–0.04) | ||